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Rejection of tumor cells by a robust cellular immune
response relies on production of type 1 cytokines (such as
IFN-g) and cytolytic activity of T cells. Programmed Death
1 (PD-1), a co-inhibitory receptor proposed to represent
T cell dysfunction, is highly expressed on tumor infiltrat-
ing lymphocytes (TIL) [1], and may reflect T cell exhaus-
tion marked by decreased proliferation, production of type
1 cytokines and poor cytolytic activity [2]. T-bet, a T-box
transcription factor which can be activated by phosphory-
lated signal transducers and activators of transcription
1 (p-STAT1), plays an important role in Tc1/Th1 skewing.
Although anti-PD-1 antibodies enhance IFN-g secretion
after TCR stimulation [3], the mechanistic link between
PD-1 and Tc1/Th1 skewing remains unclear. In prospec-
tively collected cancer tissues, TIL manifested dampened
Tc1/Th1 skewing and activation compared to PBL
(Figure 1 and 2). In addition, PD-1 triggering using PD-L1
coated beads further suppressed TCR-stimulated upregu-
lation of p-STAT1, T-bet and p-S6 as well as Th1 cyto-
kines, while PD-1 blockade reversed suppressive effects of
PD-1: PD-L1 ligation (Figure 3). We also found that Src
homology-2 domain-containing phosphatase (SHP-2) is
higher in TIL than in PBL, tightly correlates with PD-1
expression (Figure 4), and negatively regulates STAT1 and
T-bet activation (Figure 5). Thus, the PD-1/SHP-2/
p-STAT1/T-bet axis provides an important mechanism
for PD-1 suppression of type 1 immunity at tumor sites.
PD-1 blocking Abs, which are clinically effective in several
solid cancers, should improve T cell-based cancer immu-
notherapy by restoring robust type 1 immunity and T cell
activation to reverse immunosuppression in the tumor
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Figure 1 CD8+ TIL have dampened Tc1 phenotypic responses
and activation compared to PBL. p-STAT1, T-bet, p-STAT4 and p-
S6 levels in CD8+ PBL and TIL from HNC patients were analyzed by
intracellular flow cytometry. Representative figures (A) and summary
data (B) show percentage of p-STAT1 (Y701)+ (n = 15), T-bet+ (n =
16), p-STAT4 (Y693)+ (n = 7) and p-S6 (S235/236)+ (n = 13) cells in
CD8+ TIL compared with paired PBL at baseline. Total PBL and TIL
were stimulated with anti-CD3/-CD28/hIgG1 beads (bead: cell= 10:1)
for 48hrs and then p-STAT1, T-bet and p-S6 were tested by flow
cytometry. Representative figures (C) and summary data (D) of
percentage of p-STAT1 (Y701)+, T-bet+ and p-S6 (S235/236)+ (n =
6) cells in CD8+ TIL compared with paired PBL post-stimulation are
shown. Statistical significance was determined by Wilcoxon (non-
parametric paired) test. *p < 0.05, **p < 0.01, ***p < 0.001.
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microenvironment. SHP-2 inhibitory strategies may also
be useful to improve type 1-biased TIL.
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Figure 2 CD4+ TIL show abortive Th1 differentiation and low
activation compared with PBL. p-STAT1, T-bet, p-STAT4 and p-S6
levels in CD4+ PBL and TIL from HNC patients were analyzed by
intracellular flow cytometry. Representative figures (A) and summary
data (B) show percentage of p-STAT1 (Y701)+ (n = 15), T-bet+ (n =
16), p-STAT4 (Y693)+ (n = 7) and p-S6 (S235/236)+ (n = 13) cells in
CD4+ TIL compared with paired PBL at baseline. Total PBL and TIL
were stimulated with anti-CD3/-CD28/hIgG1 beads (bead: cell= 10:1)
for 48hrs and then p-STAT1, T-bet and p-S6 were tested by flow
cytometry. Representative figures (C) and summary data (D) of
percentage of p-STAT1 (Y701)+, T-bet+ and p-S6 (S235/236)+ (n =
6) cells in CD4+ TIL compared with paired PBL post-stimulation are
shown. Statistical significance was determined by Wilcoxon (non-
parametric paired) test. *p < 0.05, **p < 0.01.
Figure 3 PD-1 ligation with bead-coated PD-L1 suppressed
TCR-stimulated up-regulation of p-STAT1, T-bet and
production of Th1 cytokines, while anti-PD-1 blockade could
reverse the suppressive effects of PD-1. Total TIL were stimulated
with anti-CD3/-CD28/hIgG1 or anti-CD3/-CD28/PD-L1 coated beads
(bead: cell=10:1) for 48h in the presence of 100ug/mL hIgG4 or
anti-PD-1 (BMS-936558), then p-STAT1, T-bet and p-S6 were
analyzed by flow cytometry. Summary data of frequency of p-STAT1
(Y701)+ (A), T-bet+ (B) and p-S6 (S235/236)+ (C) in CD8+ and CD4+
TIL with indicated conditions is shown (n=7). Supernatants of TIL
stimulated with anti-CD3/-CD28/hIgG1 or anti-CD3/-CD28/PD-L1
coated beads (bead: cell=10:1) for 48h in the presence of 100ug/mL
hIgG4 or anti-PD-1 (BMS-936558) were collected and stored at -80°.
Th1 (IFN-g and IL-2) and Th2 (IL-10) cytokines in the supernatants
were determined by Luminex. Summary data of amount of IFN-γ
(D), IL-2 (E) and IL-10 (F) in the supernatants of TIL cultured under
indicated conditions is shown. The graphs present the mean ± SEM
from 8 HNC patients. Statistical significance was determined by
Wilcoxon (non-parametric paired) test. *p<0.05, **p<0.01.
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Figure 4 SHP-2 activation by fusaruside suppresses p-STAT1/
T-bet and production of Th1 cytokines upon TCR stimulation.
Total TIL were stimulated with anti-CD3/-CD28/hIgG1 beads (bead:
cell = 10:1) or anti-CD3/-CD28/PD-L1 beads plus 100 ug/mL anti-PD-
1 blockade (BMS-936558) for 48 h in the presence of 50 uM
fusaruside or DMSO. Then p-STAT1 and T-bet were analyzed by flow
cytometry. Supernatants were collected and stored at -80°C Th1
(IFN-g-and IL-2) and Th2 (IL-10) cytokines in the supernatants were
determined by Luminex. A) Summary data of frequency of p-STAT1
+ and T-bet+ cells in CD8+ and CD4+ TIL at different conditions is
shown (n = 6). B) Summary data of amount of IFN-g (n = 8), IL-2
(n = 4) and IL-10 (n = 8) in the supernatants of TIL cultured under
indicated conditions. The graphs present the mean±SEM from
different HNC patients. Statistical significance was determined by
Wilcoxon (non-parametric paired) test. *p < 0.05, **p < 0.01.
Figure 5 SHP-2 activation by fusaruside suppresses p-STAT1/T-
bet and production of Th1 cytokines upon TCR stimulation.
Total TIL were stimulated with anti-CD3/-CD28/hIgG1 beads (bead:
cell = 10:1) or anti-CD3/-CD28/PD-L1 beads plus 100 ug/mL anti-PD-
1 blockade (BMS-936558) for 48 h in the presence of 50 uM
fusaruside or DMSO. Then p-STAT1 and T-bet were analyzed by flow
cytometry. Supernatants were collected and stored at -80. Th1 (IFN-g
and IL-2) and Th2 (IL-10) cytokines in the supernatants were
determined by Luminex. A) Summary data of frequency of p-STAT1
+ and T-bet+ cells in CD8+ and CD4+ TIL at different conditions is
shown (n = 6). B) Summary data of amount of IFN-g (n = 8), IL-2 (n
= 4) and IL-10 (n = 8) in the supernatants of TIL cultured under
indicated conditions. The graphs present the mean±SEM from
different HNC patients. Statistical significance was determined by
Wilcoxon (non-parametric paired) test. *p < 0.05, **p < 0.01.
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